Biogen will invest an additional $2 billion into its North Carolina manufacturing facilities, joining a growing list of drugmakers ramping up U.S. production as tariff threats loom under President Donald Trump.
The biotech firm said Monday the new investment will boost capacity at its Research Triangle Park (RTP) campus, its largest manufacturing hub, to support the production of therapies for multiple sclerosis, Alzheimer’s, and new gene-targeting treatments.
Biogen’s announcement comes as the White House considers imposing tariffs of up to 200% on imported medicines. While drugs have so far avoided Trump’s tariff regime, the president has repeatedly floated the idea as part of efforts to strengthen domestic pharmaceutical production.
Other drugmakers—like Eli Lilly, Merck, and Roche—have similarly announced large U.S. investments in recent months.
Biogen’s North Carolina expansion will include new fill-finish capabilities, automation upgrades, and AI-powered systems to streamline drug development. The company has already spent $10 billion building out its RTP facilities.
Analysts see the move as both a strategic supply-chain play and a bid to reassure policymakers. As political pressure mounts to reduce reliance on foreign pharmaceutical sources, companies are racing to position U.S.-based operations at the center of their future growth strategies.
